Board of Directors | Wittycell

Homepage > Company > People > Board of Directors

Miguel Sieler	Served in various senior positions with Bayer Group from 1975 to 2008 in Iran, Korea, Germany, Belgium, Brazil and France. CEO of Bayer Pharma in France from 1995 to 1998 CEO of Bayer Group in France from 1998 to 2008 Board member of Nexity SA Miguel Sieler graduated from law school at the University of Tubingen, Germany and from the Institut d'Etudes Politiques de Paris, France.

Miguel Sieler joins Wittycell as Chairman of its Board of Directors. He succeeds Philippe Pouletty MD, CEO of Truffle Capital. Miguel Sieler brings an impressive track record and 30 years of chemistry & pharmaceutical industry experience. Miguel Sieler joined Bayer in 1976 as a sales manager in Germany and progressed through a number of international management positions to become the group's CEO in South Korea and then France (from 1995 to 2008). Miguel Sieler has also committed to a number of economic development activities, notably as Vice-Chairman of the Board at the Union des Industrie Chimiques chemical industry body, He has also pursued this commitment as a member of the "Club des Dirigeants" executive club and has participated in working groups on increasing France's attractiveness for inward investment. He is also a Board and Remuneration Committee member at Nexity SA and a Board Member at Ethypharm.


Gwyn Davies, MA PhD	Chairman European Adjuvant Advisory Committee Consultant to Pharma and Biotech Industries Honorary Senior Lecturer, St George’s University of London MA PhD from the University of Oxford

Gwyn Davies has many years’ experience in the discovery and industrial development of immunomodulators as novel vaccine adjuvants. He made major contributions to both R&D and business development of adjuvants at OM PHARMA, where he became joint Head of R&D. Gwyn Davies has also worked in academic research at Oxford and in Geneva and is currently an Honorary Senior Lecturer at St George’s University of London. He has published in the fields of protein chemistry and immunology and patented immune modulators. He acts as a consultant to Pharma and Biotech companies and is currently Chairman of the European Adjuvant Advisory Committee.


Eszter Nagy, MD PhD	Co-Founder and CSO of Arsanis Inc Former Senior VP, Global Head of Research at Intercell MD from the University Medical School of Pécs (Hungary), PhD in molecular biology

Eszter Nagy has more than a decade long experience in the discovery and pre-clinical development of novel vaccines, adjuvants and anti-infective monoclonal antibodies. She made fundamental contributions to the technology platforms developed at Intercell for the identification of bacterial antigens and novel adjuvant/delivery systems between 1999 and 2010. Previously, Eszter Nagy worked in academic research for 10 years in the fields of molecular biology, cellular immunology and cellular physiology at several institutions in the US and Hungary. Eszter Nagy has published in the fields of anti-microbial immunity, bacterial pathogenesis and antigen discovery for vaccine development. She is an inventor on more than twenty patents in the field of vaccines and biotechnology.


Philippe Pouletty, MD	General Partner Biotech of Truffle Venture. Chairman of Europabio (European Biotech Industry Association). MD from University of Paris V, laureate of the American Liver Foundation.

Philippe Pouletty is a Biotech industry veteran with dual experience in Silicon Valley and France. He is Founder of 3 biotechnology companies (two are public) : SangStat, est. 1988 (California), quoted on NASDAQ in 1993, Conjuchem, est. 1993 (California), quoted in Canada in 2000 and DrugAbuse Sciences, est. 1995 (USA + France). Philippe Pouletty is Limited partner of US VC funds, Sequoia, Sofinnova, Partech, JP Morgan. Inventor of 22 patents, Pouletty is chairman of the “Conseil Superieur de l’innovation”.


Vincent Serra, PhD	Co-Founder, CEO and CSO of Wittycell SAS. PhD in Immunology, Grenoble I. Member of The European Adjuvant Advisory Committee (EAAC) Vice President of Biosupport.

Vincent Serra is an experienced biotechnology executive. Prior to creating Wittycell, Vincent Serra spent six years as Vice President European Operations of the Anosys group, in charge of R&D and production for an immunotherapeutic vaccine, encompassing IP, QA/QC, manufacturing, regulatory, and Phase I and Phase II clinical trials in US and Europe. Vincent Serra has strong expertise in cellular immunology and biochemistry. Vincent Serra also has experience from the microbiological department of the Pulp and Paper Research & Technical Center Industry where he supervised assay development for novel bacteria detection methods and paper downstream process development.